We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shares of Santarus climbed Monday after the specialty pharmaceutical company announced an agreement with GlaxoSmithKline to commercialize prescription and over-the-counter immediate-release heartburn reliever Zegerid. TheStreet.com
